Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | The genetic landscape of MDS and impact on treatment

Valeria Santini • 18 Jun 2021
EHA 2021
Myelodysplastic Syndromes

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the genomic landscape of myelodysplastic syndromes (MDS), highlighting research into the development of a scoring system for MDS which integrates the IPSS-R with the clinical and molecular characteristics of MDS. Dr Santini comments on the impact of mutations such as SF3B1 and TP53 on prognosis, as well as giving an overview of the role of biomarkers in MDS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals